APAC Healthcare Weekly (Feb 2)- Daiichi Sankyo, Eisai, Nippon Shinyaku, Shionogi, Celltrion
APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...
711 Views
APAC Healthcare Weekly (Jan 26)- Daiichi Sankyo, Sumitomo Pharma, Fosun Pharma, SK Bioscience, Hugel
APAC healthcare companies got approvals for new products as well as clinical trials. The companies continued with acquisitions and collaborations...
486 Views
Daiichi Sankyo (4568 JP): US Approval for Second ADC Drug to Drive Accelerated Growth
​FDA approves Daiichi Sankyo's Datroway for second-line treatment of breast cancer. Supported by AstraZeneca's commercialization expertise, the...
393 Views
Wuxi XDC Placement - A Repeat of Biologics Placement Saga, Last Deal Did Well
WuXi AppTec (2359 HK) aims to raise around US$150m via selling around 3% stake in WuXi XDC Cayman (2268 HK). It has sold earlier in Nov 24 as well.
720 Views
APAC Healthcare Weekly (Dec 29)- Wuxi AppTech, SK Bioscience, Kaken Pharma, Shionogi, Daiichi Sankyo
Wuxi AppTech is selling its US and UK-based cell and gene therapy unit. APAC healthcare companies continued their licensing activities. Approvals...
562 Views